William Blair Issues Optimistic Forecast for EW Earnings

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at William Blair upped their Q4 2025 earnings estimates for Edwards Lifesciences in a research note issued to investors on Thursday, December 5th. William Blair analyst M. Andrew now forecasts that the medical research company will earn $0.64 per share for the quarter, up from their previous forecast of $0.63. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.55 per share.

Several other brokerages have also recently issued reports on EW. Truist Financial restated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday. Canaccord Genuity Group boosted their target price on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a report on Thursday. Barclays increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. The Goldman Sachs Group boosted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Royal Bank of Canada raised their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $78.35.

Edwards Lifesciences Trading Down 1.2 %

NYSE EW opened at $71.53 on Monday. The firm’s fifty day moving average is $68.65 and its two-hundred day moving average is $74.41. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $42.19 billion, a PE ratio of 10.32, a P/E/G ratio of 4.17 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the business posted $0.59 EPS. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 40,000 shares of company stock worth $2,657,000. 1.29% of the stock is owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

A number of hedge funds have recently bought and sold shares of EW. Franklin Resources Inc. lifted its stake in shares of Edwards Lifesciences by 2.3% during the 3rd quarter. Franklin Resources Inc. now owns 1,196,059 shares of the medical research company’s stock worth $83,282,000 after purchasing an additional 27,193 shares during the period. Peapack Gladstone Financial Corp lifted its position in Edwards Lifesciences by 108.0% during the third quarter. Peapack Gladstone Financial Corp now owns 293,758 shares of the medical research company’s stock worth $19,385,000 after buying an additional 152,539 shares during the period. Tidal Investments LLC boosted its stake in Edwards Lifesciences by 0.7% in the 3rd quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company’s stock worth $2,609,000 after buying an additional 275 shares during the last quarter. Destination Wealth Management boosted its stake in Edwards Lifesciences by 2.8% in the 3rd quarter. Destination Wealth Management now owns 7,012 shares of the medical research company’s stock worth $463,000 after buying an additional 193 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB grew its holdings in Edwards Lifesciences by 147.0% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company’s stock valued at $601,000 after buying an additional 5,420 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.